Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Biomea Fusion is a clinical-stage biopharmaceutical company developing novel small molecules to cure metabolic diseases. Its proprietary FUSION System platform has created a pipeline of covalent candidates, which are drug molecules that form permanent bonds with their target proteins in the body, offering potential advantages over traditional non-covalent drugs. Lead asset icovamenib is in clinical trials for type 2 and type 1 diabetes (T2D; T1D), aiming to address critical unmet needs in the space. The company is also advancing next-generation asset BMF-650 towards the clinic, for diabetes and obesity. The treatment markets for these disease areas are projected to reach c $134bn and c $105bn, respectively, by 2030. Multiple pipeline catalysts are anticipated for Biomea throughout 2025.</p>

Biomea Fusion is a clinical-stage biopharmaceutical company developing novel small molecules to cure metabolic diseases. Its proprietary FUSION System platform has created a pipeline of covalent candidates, which are drug molecules that form permanent bonds with their target proteins in the body, offering potential advantages over traditional non-covalent drugs. Lead asset icovamenib is in clinical trials for type 2 and type 1 diabetes (T2D; T1D), aiming to address critical unmet needs in the space. The company is also advancing next-generation asset BMF-650 towards the clinic, for diabetes and obesity. The treatment markets for these disease areas are projected to reach c $134bn and c $105bn, respectively, by 2030. Multiple pipeline catalysts are anticipated for Biomea throughout 2025.

Biomea Fusion — An innovative approach to diabetes and obesity

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul>
<li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li>
<li>Last week, BMY received landmark antipsychotic approval, while BHVN finally scored a win in rare genetic SCA.</li>
<li>AMGN had approvable data in atopic dermatitis and gMG, but not enough to dethrone REGN and ARGX. </li>
</ul>


We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.
Last week, BMY received landmark antipsychotic approval, while BHVN finally scored a win in rare genetic SCA.
AMGN had approvable data in atopic dermatitis and gMG, but not enough to dethrone REGN and ARGX. 


Biopharma Week in Review - September 30, 2024

United States

Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Biomea Fusion (BMEA US)

Biomea Fusion — An innovative approach to diabetes and obesity

Biomea Fusion is a clinical-stage biopharmaceutical company developing novel small molecules to cure metabolic diseases. Its proprietary FUSION...

Edison Investment Research

Biopharma Week in Review - September 30, 2024

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A. Last week, BMY received...

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)